Asset

TIRASEMTIV

Cytokinetics Incorporated Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (3)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT01378676phase2completed2011-06-012012-03-01CytokineticsA Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01486849phase2completed2011-11-012012-03-01CytokineticsDose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01709149phase2completed2012-10-012014-03-01CytokineticsStudy of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)